There is only limited data on cytomegalovirus (CMV) prophylaxis with high-dose (HD) aciclovir after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis on a total of 179 patients who underwent their allo-HSCT with HD-aciclovir prophylaxis at our center. A clinically significant CMV infection (cs-CMVi) was observed in 56 (31%) cases with a median time of 49 (range 25-147) days after HSCT. A significantly higher CMV infection rate was observed in seropositive recipients with a seronegative donor (74%) compared to seropositive recipients with a seropositive donor, and seronegative recipients with seropositive and seronegative donors (24%, 18%, 7% respectively; p < 0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir's adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.

Department of Internal Medicine Hematology and Oncology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Zobrazit více v PubMed

Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–38. doi: 10.1182/blood-2015-11-679639. PubMed DOI PMC

Chen K, Cheng MP, Hammond SP, Einsele H, Marty FM. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018;2:2159–75. doi: 10.1182/bloodadvances.2018016493. PubMed DOI PMC

Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7) Lancet Infect Dis. 2019;19:e260–72. doi: 10.1016/S1473-3099(19)30107-0. PubMed DOI

Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, et al. American Society for Transplantation and Cellular Therapy Series: #3-Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transpl Cell Ther. 2021;27:707–19. doi: 10.1016/j.jtct.2021.05.001. PubMed DOI

Erard V, Guthrie KA, Seo S, Smith J, Huang M, Chien J, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61:31–9. doi: 10.1093/cid/civ215. PubMed DOI PMC

Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1309–14. doi: 10.1016/j.bbmt.2010.03.020. PubMed DOI

Reed DR, Petroni GR, West M, Jones C, Alfaraj A, Williams PG, et al. Prophylactic pretransplant ganciclovir to reduce cytomegalovirus infection after hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2023;16:61–9. doi: 10.1016/j.hemonc.2021.05.001. PubMed DOI PMC

Bacigalupo A, Tedone E, Van Lint MT, Trespi G, Lonngren M, Sanna MA, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant. 1994;13:783–8. PubMed

Bregante S, Bertilson S, Tedone E, Van Lint MT, Trespi G, Mordini N, et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant. 2000;26:23–9. doi: 10.1038/sj.bmt.1702450. PubMed DOI

Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant. 2002;30:945–51. doi: 10.1038/sj.bmt.1703770. PubMed DOI

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44. doi: 10.1056/NEJMoa1706640. PubMed DOI

Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M, et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet. 1983;2:706–8. doi: 10.1016/s0140-6736(83)92248-1. PubMed DOI

Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med. 1988;318:70–5. doi: 10.1056/NEJM198801143180202. PubMed DOI

Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Rañada JM, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet. 1994;343:749–53. doi: 10.1016/s0140-6736(94)91835-x. PubMed DOI

Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Yeşilipek A. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Bone Marrow Transplant. 2004;33:931–5. doi: 10.1038/sj.bmt.1704463. PubMed DOI

Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, et al. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment. Jpn J Infect Dis. 2006;59:216–21. PubMed

Nakamura R, Cortez K, Solomon S, Battiwalla M, Gill VJ, Hensel N, et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30:235–42. doi: 10.1038/sj.bmt.1703648. PubMed DOI PMC

Ljungman P, de La Camara R, Milpied N, Volin L, Russell CA, Crisp A, et al. Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99:3050–6. doi: 10.1182/blood.v99.8.3050. PubMed DOI

Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA, Riffkin I, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118:5689–96. doi: 10.1182/blood-2011-06-361618. PubMed DOI PMC

Valcárcel D, Sureda A. Graft failure. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Chapter 41, 7th ed. Cham (CH): Springer; 2019. PubMed

Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25:151–69. doi: 10.1016/j.hoc.2010.11.011. PubMed DOI PMC

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12:322–9. doi: 10.1111/j.1399-3062.2010.00504.x. PubMed DOI

Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135:1619–29. doi: 10.1182/blood.2019000956. PubMed DOI PMC

Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122:3359–64. doi: 10.1182/blood-2013-05-499830. PubMed DOI

Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009;113:6465–76. doi: 10.1182/blood-2009-02-203307. PubMed DOI PMC

Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant. 2015;21:2008–16. doi: 10.1016/j.bbmt.2015.07.019. PubMed DOI

Turki AT, Tsachakis-Mück N, Leserer S, Crivello P, Liebregts T, Betke L, et al. Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG. Blood Adv. 2022;6:28–36. doi: 10.1182/bloodadvances.2021005509. PubMed DOI PMC

Liu LW, Yn A, Gao F, Olson M, Crain M, Abboud R, et al. Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality. Transpl Cell Ther. 2022;28:510.e1–9. doi: 10.1016/j.jtct.2022.05.020. PubMed DOI

Anderson A, Raja M, Vazquez N, Morris M, Komanduri K, Camargo J. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transplant. 2020;34:e13866. doi: 10.1111/ctr.13866. PubMed DOI

Hiraishi I, Ueno R, Watanabe A, Maekawa S. Safety and effectiveness of letermovir in allogenic hematopoietic stem cell transplantation recipients: interim report of post-marketing surveillance in Japan. Clin Drug Investig. 2021;41:1075–86. doi: 10.1007/s40261-021-01096-5. PubMed DOI PMC

Yoshimura H, Satake A, Ishii Y, Ichikawa J, Saito R, Konishi A, et al. Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: a single-center retrospective analysis. J Infect Chemother. 2022;28:1317–23. doi: 10.1016/j.jiac.2022.05.019. PubMed DOI

Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138:34–43. doi: 10.1182/blood.2020009396. PubMed DOI PMC

Marzolini MAV, Mehra V, Thomson KJ, Tholouli E, Bloor AJC, Parker A, et al. Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting. Blood Adv. 2021;5:4500–3. doi: 10.1182/bloodadvances.2021005637. PubMed DOI PMC

Blyth E, Withers B, Clancy L, Gottlieb D. CMV-specific immune reconstitution following allogeneic stem cell transplantation. Virulence. 2016;7:967–80. doi: 10.1080/21505594.2016.1221022. PubMed DOI PMC

Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060–7. doi: 10.1182/blood-2002-11-3472. PubMed DOI

Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Infectious Diseases Working Party EBMT. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020;55:126–36. doi: 10.1038/s41409-019-0624-z. PubMed DOI PMC

Giménez E, Torres I, Albert E, Piñana JL, Hernández-Boluda JC, Solano C, et al. Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): a systematic review, meta-analysis, and meta-regression analysis. Am J Transplant. 2019;19:2479–94. doi: 10.1111/ajt.15515. PubMed DOI